Idiopathic Hypertension: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

PUNE, INDIA, September 26, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

Complete Report @ https://www.wiseguyreports.com/reports/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Get Sample Report @ https://www.wiseguyreports.com/sample-request/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016

Table of Content
Therapeutics Development 9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic (Essential) Hypertension - Products under Development by Companies 14
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15
Actelion Ltd 15
Bayer AG 16
Chong Kun Dang Pharmaceutical Corp. 17
Daiichi Sankyo Company, Limited 18
Eli Lilly and Company 19
HanAll Biopharma Co., Ltd. 20
Innopharmax Inc. 21
Lee's Pharmaceutical Holdings Limited 22
PhaseBio Pharmaceuticals, Inc. 23
Quantum Genomics SA 24
Takeda Pharmaceutical Company Limited 25
Idiopathic (Essential) Hypertension - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
(amlodipine besylate + candesartan cilexetil) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(atorvastatin calcium + losartan potassium) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(candesartan cilexetil + nifedipine) - Drug Profile 40

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649785
Continued…

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here